Abstract:Protein aggregation is common to dozens of diseases including prionoses, diabetes, Parkinson’s and Alzheimer’s. Over the past 15 years, there has been a paradigm shift in understanding the structural basis for these proteinopathies. Precedent for this shift has come from investigation of soluble Aβ oligomers (AβOs), toxins now widely regarded as instigating neuron damage leading to Alzheimer’s dementia. Toxic AβOs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. The AD-like cellular pathologies induced by AβOs suggest their impact provides a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Alternative ideas for triggering mechanisms are being actively investigated. Some research favors insertion of AβOs into membrane, while other evidence supports ligand-like accumulation at particular synapses. Over a dozen candidate toxin receptors have been proposed. AβO binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca2+ overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of AβOs have been identified, a remaining question is which oligomer is the major pathogenic culprit. The possibility has been raised that more than one species plays a role. Despite some key unknowns, the clinical relevance of AβOs has been established, and new studies are beginning to point to co-morbidities such as diabetes and hypercholesterolemia as etiological factors. Because pathogenic AβOs appear early in the disease, they offer appealing targets for therapeutics and diagnostics. Promising therapeutic strategies include use of CNS insulin signaling enhancers to protect against the presence of toxins and elimination of the toxins through use of highly specific AβO antibodies. An AD-dependent accumulation of AβOs in CSF suggests their potential use as biomarkers and new AβO probes are opening the door to brain imaging. Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer’s disease.

The Alzheimer’s Aβ peptide forms biomolecular condensates that trigger amyloid aggregation

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Aggregation of the amyloid-β peptide (Aβ40) within condensates generated through liquid–liquid phase separation

Energy Landscapes of the Monomer and Dimer of the Alzheimer’s Peptide Aβ(1–28)

Structural, morphological, and kinetic studies of β-amyloid peptide aggregation on self-assembled monolayers.

Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules

Characterization of the Conformations of Amyloid Beta 42 in Solution That May Mediate Its Initial Hydrophobic Aggregation

Amyloid-α Peptide Formed through Alternative Processing of the Amyloid Precursor Protein Attenuates Alzheimer's Amyloid-β Toxicity via Cross-Chaperoning

Aggregation mechanisms and molecular structures of amyloid‐β in Alzheimer's disease

Aβ-oligomers: A potential therapeutic target for Alzheimer's disease

The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding

Polymorphism in Alzheimer Aβ Amyloid Organization: Insight into Aβ Aggregation

Membrane-assisted Aβ40 aggregation pathways

Intra-membrane Oligomerization and Extra-membrane Oligomerization of Amyloid-β Peptide Are Competing Processes As a Result of Distinct Patterns of Motif Interplay

Amyloid-beta aggregates formed at polar-nonpolar interfaces differ from amyloid-beta protofibrils produced in aqueous buffers

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Spontaneous formation of β-sheet nano-barrels during the early aggregation of Alzheimer’s amyloid beta

Compilation and Analysis of Enzymes, Engineered Antibodies, and Nanoparticles Designed to Interfere with Amyloid-Beta Aggregation

Pathway Complexity of Alzheimer's β-Amyloid Aβ16-22 Peptide Assembly

Conformational Changes and Unfolding of β-Amyloid Substrates in the Active Site of γ-Secretase

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis